CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

被引:5
|
作者
Yi, Yonglin [1 ]
Qiu, Zhengang [2 ]
Yao, Zifu [1 ,3 ]
Lin, Anqi [1 ]
Qin, Yimin [1 ]
Sha, Ruizhan [1 ]
Wei, Ting [1 ]
Wang, Yanru [1 ]
Cheng, Quan [4 ]
Zhang, Jian [1 ]
Luo, Peng [1 ]
Shen, Weitao [1 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou, Peoples R China
[2] Gannan Med Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Peoples R China
[3] Southern Med Univ, Clin Med Sch 1, Guangzhou, Peoples R China
[4] Ctr South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Peoples R China
来源
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2022年 / 9卷
基金
中国国家自然科学基金;
关键词
small cell lung cancer; CAMSAP1; platinum-based chemotherapy; drug sensitivity; biomarker; ACTIVATED PROTEIN-KINASE; TGF-BETA; B-CELLS; EXPRESSION; CHEMORESISTANCE; IMMUNOTHERAPY; SURVIVAL; FAMILY; MECHANISMS; MANAGEMENT;
D O I
10.3389/fcell.2021.770811
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Platinum-based chemotherapy is the first-line treatment for small cell lung cancer (SCLC). However, due to patients developing a resistance to the drug, most experience relapse and their cancer can become untreatable. A large number of recent studies have found that platinum drug sensitivity of various cancers is affected by specific gene mutations, and so with this study, we attempted to find an effective genetic biomarker in SCLC patients that indicates their sensitivity to platinum-based drugs. To do this, we first analyzed whole exome sequencing (WES) and clinical data from two cohorts to find gene mutations related to the prognosis and to the platinum drug sensitivity of SCLC patients. The cohorts used were the Zhujiang cohort (N = 138) and the cohort reported by George et al. (N = 101). We then carried out gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) to investigate possible molecular mechanisms through which these gene mutations affect patient prognosis and platinum drug sensitivity. We found that for SCLC patients, CAMSAP1 mutation can activate anti-tumor immunity, mediate tumor cell apoptosis, inhibit epithelial-mesenchymal transition (EMT), improve prognosis, and improve platinum drug sensitivity, suggesting that CAMSAP1 mutation may be a potential biomarker indicating platinum drug sensitivity and patient prognosis in SCLC.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients
    Zhang, Shiheng
    He, Le
    Dai, Nan
    Guan, Wei
    Shan, Jinlu
    Yang, Xueqin
    Zhong, Zhaoyang
    Qing, Yi
    Jin, Feng
    Chen, Chuan
    Yang, Yuxin
    Wang, Hongyi
    Baugh, Laura
    Tell, Gianluca
    Wilson, David M., III
    Li, Mengxia
    Wang, Dong
    ONCOTARGET, 2016, 7 (47) : 77482 - 77494
  • [22] Sequence Variation in Mature MicroRNA-499 Confers Unfavorable Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy
    Qiu, Fuman
    Yang, Lei
    Ling, Xiaoxuan
    Yang, Rongrong
    Yang, Xiaorong
    Zhang, Lisha
    Fang, Wenxiang
    Xie, Chenli
    Huang, Dongsheng
    Zhou, Yifeng
    Lu, Jiachun
    CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1602 - 1613
  • [23] Genome-Wide Association Study of Prognosis in Advanced Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy
    Hu, Lingmin
    Wu, Chen
    Zhao, Xueying
    Heist, Rebecca
    Su, Li
    Zhao, Yang
    Han, Baohui
    Cao, Songyu
    Chu, Minjie
    Dai, Juncheng
    Dong, Jing
    Shu, Yongqian
    Xu, Lin
    Chen, Yijiang
    Wang, Yi
    Lu, Feng
    Jiang, Yue
    Yu, Dianke
    Chen, Hongyan
    Tan, Wen
    Ma, Hongxia
    Chen, Jiaping
    Jin, Guangfu
    Wu, Tangchun
    Lu, Daru
    Christiani, David C.
    Lin, Dongxin
    Hu, Zhibin
    Shen, Hongbing
    CLINICAL CANCER RESEARCH, 2012, 18 (19) : 5507 - 5514
  • [24] Molecular profiles of predictive biomarkers for platinum-based chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
    Seyedabadi, NiloofarTaleghani
    Shoushtari, Sara YousefZadeh
    Soofi, Asma
    Arabpour, Javad
    Shams, Zinat
    Akhavan, Homa
    Hosseini-Asl, Saied
    META GENE, 2022, 31
  • [25] Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
    Lima, Aurea
    Seabra, Vitor
    Martins, Sandra
    Coelho, Ana
    Araujo, Antonio
    Medeiros, Rui
    MOLECULAR BIOLOGY REPORTS, 2014, 41 (05) : 3349 - 3357
  • [26] Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients
    Zhao, Xin
    Zhang, Zhiqiang
    Yuan, Yan
    Yuan, Xiaomei
    TUMOR BIOLOGY, 2014, 35 (08) : 8335 - 8341
  • [27] ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
    Kalikaki, Aristea
    Voutsina, Alexandra
    Koutsopoulos, Anastasios
    Papadaki, Chara
    Sfakianaki, Maria
    Yachnakis, Emmanouel
    Xyrafas, Alexandros
    Kotsakis, Athanasios
    Agelaki, Sofia
    Souglakos, John
    Mavroudis, Dimitrios
    Georgoulias, Vassilis
    CANCER INVESTIGATION, 2015, 33 (04) : 107 - 113
  • [28] Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease
    Hirotsugu Kenmotsu
    Tateaki Naito
    Keita Mori
    Ryo Ko
    Akira Ono
    Kazushige Wakuda
    Hisao Imai
    Tetsuhiko Taira
    Haruyasu Murakami
    Masahiro Endo
    Toshiaki Takahashi
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 521 - 526
  • [29] Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Mori, Keita
    Ko, Ryo
    Ono, Akira
    Wakuda, Kazushige
    Imai, Hisao
    Taira, Tetsuhiko
    Murakami, Haruyasu
    Endo, Masahiro
    Takahashi, Toshiaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 521 - 526
  • [30] INTRINSIC AND ACQUIRED RESISTANCE PATTERNS IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH PLATINUM-BASED CHEMOTHERAPY
    Stewart, David J.
    Saintigny, Pierre
    Lu, Charles
    Goss, Glenwood
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S862 - S863